Effect of Traditional Chinese Medicine Product, QiangGuYin, on Bone Mineral Density and Bone Turnover in Chinese Postmenopausal Osteoporosis

Abstract EN

Introduction.

The aim of this study was to investigate the efficacy of herbal formula QiangGuYin (QGY) in postmenopausal women.

Materials and Methods.

A total of 240 participants from six clinical centers were randomly to receive alendronate 70 mg/week, QGY granules 20 g/day, and placebo.

Primary end points were BMD changes over 6 and 12 months; secondary end points were bone turnover markers changes at 3, 6, 9, and 12 months.

Safety was monitored by clinical adverse events reported during the follow-up.

Results.

Of 240 women recruited, 218 completed the study.

Significant BMD increases from baseline were observed over 6 and 12 months at each observed part both in QGY and alendronate compared with placebo (p<0.01).

Alendronate-treated subjects had significant decreases in β-CTX compared to QGY-treated subjects at each time point assessed (p<0.01).

Reduction in t-P1NP was only observed in the QGY group at 3 and 6 months (−23.81% and −3.07%, resp.).

No significant difference was observed in the overall incidence of clinical adverse events among the alendronate group and the QGY group (5.0% versus 7.5%, p=0.513).

Conclusion.

1-Year treatment with QGY demonstrated a safe statistical increase in BMD and new balance may be rebuilt after 9 months.

This trail is registered with ChiCTR-POC-16008026.